|

GFH375 Clinical Trials

3 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Genfleet Therapeutics (Shanghai) Inc.3

Indications

  • Cancer3
  • KRAS G12D Mutations1
  • KRAS G12D Mutation1
  • NSCLC (Non-small Cell Lung Cancer)1
  • Metastatic Pancreatic Cancer1

Other3 trials

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Phase 1/2
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
Phase 3
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.